New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Diabetic peripheral neuropathy (DPN) is a common chronic complication of diabetes mellitus. It leads to distressing and expensive clinical sequelae such as foot ulceration, leg amputation, and neuropathic pain (painful-DPN). Unfortunately, DPN is often diagnosed late when irreversible nerve injury has occurred and its first presentation may be with a diabetic foot ulcer. Several novel diagnostic techniques are available which may supplement clinical assessment and aid the early detection of DPN. Moreover, treatments for DPN and painful-DPN are limited. Only tight glucose control in type 1 diabetes has robust evidence in reducing the risk of developing DPN. However, neither glucose control nor pathogenetic treatments are effective in painful-DPN and symptomatic treatments are often inadequate. It has recently been hypothesized that using various patient characteristics it may be possible to stratify individuals and assign them targeted therapies to produce better pain relief. We review the diagnostic techniques which may aid the early detection of DPN in the clinical and research environment, and recent advances in precision medicine techniques for the treatment of painful-DPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Diabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376 · cited 2×
“Lower-limb complications of diabetes are expensive and a substantial burden for patients, potentially leading to devastating outcomes such as lower limb amputation and death (3, 4, 6).”
BackgroundPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690 · cited 7×
“Skin biopsy of the distal leg with quantification of intra-epidermal nerve fiber density (IENFD) is the gold standard technique to diagnose small fiber neuropathy (SFN) and it is also recommended for diagnosing DPN (16, 36).”
BackgroundMethodInfluentialSelf-citationDiabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 9×
“The mainstay of modern management is to control risk factors for DPN, and prevent and manage its complications (10).”
BackgroundInfluentialDyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Abbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 1×
“A Cochrane Collaboration review concluded that at doses of 60 and 120mg duloxetine is effective in treating painful-DPN, with rare serious side effects (113, 114).”
BackgroundGabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561 · cited 1×
“Gabapentin is efficacious for the treatment of pain and sleep interference in painful-DPN but has a high rate of side effects, most commonly dizziness, and somnolence (105, 106).”
BackgroundDiabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487 · cited 3×
“However, they are not currently widely available as they require specialist expertise and expensive equipment to perform (50).”
BackgroundInfluentialValidation of the Toronto Clinical Scoring System for diabetic polyneuropathy
Bril, V., & Perkins, B. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2048 · Cited by 472 · cited 2×
“, Toronto Clinical Scoring System (35).”
Demant, D. T., Lund, K., Vollert, J., Maier, C., Segerdahl, M., Finnerup, N. B., Jensen, T. S., & Sindrup, S. H. (2014) · Pain · doi:10.1016/j.pain.2014.08.014 · Cited by 440
Tesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S. H., Perkins, B. A., Baconja, M., Vinik, A. I., Boulton, A. J. M., & Neuropathy, O. B. O. T. T. E. P. O. D. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1225 · Cited by 410 · cited 3×
“Furthermore, non-pharmacological treatments may be considered to complement drug treatments, such as acupuncture, or used as a last resort in resistant cases, such as electrical spinal cord stimulator insertion (103, 121, 122).”
BackgroundMethodSelf-citationTesfaye, S., Wilhelm, S., Lledo, A., Schacht, A., Tölle, T., Bouhassira, D., Cruccu, G., Skljarevski, V., & Freynhagen, R. (2013) · Pain · doi:10.1016/j.pain.2013.05.043 · Cited by 311 · cited 1×
“A Cochrane Collaboration review concluded that at doses of 60 and 120mg duloxetine is effective in treating painful-DPN, with rare serious side effects (113, 114).”
BackgroundSelf-citationZiegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00555.x · Cited by 249 · cited 1×
“Idiopathic neuropathy is more prevalent in pre-diabetic states such as impaired glucose tolerance (IGT) (31).”
BackgroundAndersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2062 · Cited by 248
Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0012 · Cited by 167 · cited 1×
“recently found that patients with type 2 diabetes treated with insulin sensitizing therapies had a significantly reduced incidence of DPN compared with insulin providing treatments (10, 95).”
BackgroundCalles-Escandón, J., Lovato, L. C., Simons-Morton, D. G., Kendall, D. M., Pop-Busui, R., Cohen, R. M., Bonds, D. E., Fonseca, V. A., Ismail-Beigi, F., Banerji, M. A., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1471 · Cited by 160
Bouhassira, D., Wilhelm, S., Schacht, A., Perrot, S., Kosek, E., Cruccu, G., Freynhagen, R., Tesfaye, S., Lledó, A., Choy, E., et al. (2014) · Pain · doi:10.1016/j.pain.2014.08.020 · Cited by 132 · cited 1×
“Moreover, cluster analysis of patient subgroups from the COMBO-DN study using the NPSI found that the addition of pregabalin to duloxetine was effective in patients with pressing and evoked pain, but high dose duloxetine monotherapy wasmore beneficial for relief of para/dys-aesthesias (128).”
MethodSelf-citationTruini, A., Spallone, V., Morganti, R., Tamburin, S., Zanette, G., Schenone, A., De Michelis, C., Tugnoli, V., Simioni, V., Manganelli, F., et al. (2018) · Pain · doi:10.1097/j.pain.0000000000001378 · Cited by 85 · cited 1×
“However, recent studies have demonstrated strong evidence that female sex is a risk factor for painful-DPN (12, 30).”
BackgroundSelf-citation
Cited by
Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications
Zorena, K., Jachimowicz-Duda, O., Ślęzak, D., Robakowska, M., & Mrugacz, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103570 · Cited by 411
Naranjo, C., Ortega-Jiménez, P., del Reguero, L., Moratalla, G., & Failde, I. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108236 · Cited by 55
Ahmed, A., Sattar, N., & Yaghootkar, H. (2022) · Diabetic Medicine · doi:10.1111/dme.14982 · Cited by 10
Metadata
- Authors
- Yang, H., Sloan, G., Ye, Y., Wang, S., Duan, B., Tesfaye, S., & Gao, L.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-17
- Volume
- 10
- Pages
- 929-929
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2999797667
- Cited by
- 151
- References
- 23
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.